[1]Reszke R, Szepietowski JC. End- Stage Renal Disease Chronic Itch and Its Management[J]. Dermatol Clin, 2018,36(3):277-292.
[2]ErikssonD,?GoldsmithD,?TeitssonS,?et?al.?Cross-sectional?survey?in?CKD?patients?across?Europe?describing?the?association?between?quality?of?life?and?anaemia[J].?BMC?Nephrol,?2016,?17(1):97.?
[3]HoshinoJ,?MuenzD,?ZeeJ,?et?al.?Associations?of?hemoglobin?levels?with?health-related?quality?of?life,?physical?activity,?and?clinical?outcomes?in?persons?with?stage?3-5?nondialysis?CKD[J].?J?Ren?Nutr,?2020,?30(5):404-414.?
[4]Besarab A, Golper TA. Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients. ASAIO Trans 1991; 37(3):M395–6.
[5]Locatelli F, Aljama P, Bárány P,et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure[J].Nephrol Dial Transplant,2004,19 Suppl 2:ii1-47.
[6]KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target[J]. Am J Kidney Dis,2007 ,50(3):471-530.
[7]Padhi S, Glen J, Pordes BA,et al. Management of anaemia in chronic kidney disease: summary of update NICE guidance[J]. BMJ, 2021,350:h2258-2261.
[8]中国医师协会肾内科医师分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识(2018修订版)[J].中华肾脏病杂志,2018,34(11):860-866.
[9]KDIGO Clinical Practice Guideline Working Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease[J]. Kidney Int Suppl, 2012, 2: 279?335.
[10]Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease[J]. BMC Nephrol, 2017, 18(1): 345.
[11]Melissa E. Stauffer, Tao Fan. Prevalence of Anemia in Chronic Kidney Disease in the United States[J]. PLoS ONE,2014, 9(1): e84943.
[12]SARANR,LI Y, ROBINSONB, et al. US renaldatasystem 2014 annual data report: epidemiology of kidney disease in the united states[J].Am J Kidney Dis,2015,66(1):S1-305.
[13]Li Y, Shi H, Wang W- M,et al. Prevalence, awareness and treatment of anemia in Chinese patients with nondialysis chronic kidney disease .First multicenter,cross-sectional study[J]. Medicine .2016,95:24-31.
[14]Zuo L, Wang M, Hou F, et al. Anemia Management in the China Dialysis Outcomes and Practice Patterns Study[J]. Blood Purif, 2016,42(1):33-43.
[15]陈继英,唐东兴.常用血液净化方式对维持性血液透析患者残余肾功能的影响[J].中南医学科学杂志,2014,42(2):178-180.?
[16]KDIGO Clinical Practice Guideline Working Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease[J]. Kidney Int Suppl, 2021, 2: 279?335.
[17]中国医师协会肾脏内科医师分会肾性贫血指南工作组,陈香美,孙雪峰.中国肾性贫血诊治临床实践指南[J].中华医学杂志,2021,101(20):1463-1502.
[18]Hayashi T, Uemura Y, Kumagai M, et al. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA clinical evidence on renal survival in CKD patients with renal anemia (MIRACLE-CKD Study) [J]. Clin Exp Nephrol, 2019, 23(3): 349-361.
[19]Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease [J]. Clin Kidney J, 2016, 9(2): 260-267.
[20]Macdougall IC, Bock AH, Carrera F, et al. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial [J]. BMC Nephrol, 2017,18(1):24.
[21]Roger SD, Gaillard CA, Bock AH, et al. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial [J]. Nephrol Dial Transplant, 2017, 32(9):1530-1539.
[22]Karaboyas A, Morgenstern H, Pisoni RL, et al. Association between serum ferritin and mortality: findings from the USA, Japan and European dialysis outcomes and practice patterns study [J]. Nephrol Dial Transplant, 2018, 33(12):2234-2244.
[23]Wish JB, Aronoff GR, Bacon BR, et al. Positive iron balance in chronic kidney disease: how much is too much and how to tell? [J]. Am J Nephrol, 2018, 47(2): 72-83.
[24]日本透析医学会. 慢性腎臓病患者における腎性貧血治療のガイドライン[J]. 透析会誌, 2016, 49(2): 89-158.
[25]Cody JD, Hodson EM. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis [J]. Cochrane Database Syst Rev, 2016,016(1): CD003266.
[26]Nissenson AR, Swan SK, Lindberg JS, et al. Randomized,controlled trial of darbepoetin alfa for the treatmentof anemia in hemodialysis patients[J]. Am J KidneyDis, 2002, 40(1): 110-118.
[27]Akizawa T, Koshikawa S, Iwasaki M, et al. Darbepoetinalfa effectively maintains hemoglobin concentrationsat extended dose intervals relative to intravenousrHuEPO in Japanese dialysis patients[J]. Ther Apher Dial,2007, 11(3): 220-226.
[28]傅晓岑, 任红, 陈楠, 中国血液净化2022年1月第21卷第1期Chin J Blood Purif,January,2022,Vol.21,No.01.
[29]Ratcliffe LE, Thomas W, Glen J, et al. Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rational e[J].Am J Kidney Dis, 2016, 67(4): 548-558.
[30]Fishbane S, Block GA, Loram L, et al. Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia [J]. J Am Soc Nephrol, 2017, 28(6):1851-1858.
[31]Pergola PE, Fishbane S, LeWinter RD, et al. Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia [J]. Am J Hematol, 2018, 93(6):E154-E156.
[32]Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, et al. 2015 Japanese Society for Dialysis Therapy. Guidelines for renal anemia in chronic kidney disease. Renal replacement therapy 2017; 3:36.
[33]Shepshelovich D, Rozen- Zvi B, Avni T,et al. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta- analysis[J].Am J Kidney Dis,2016,68(5):677-690.
[34]Red Blood Cell Diseases Group, Chinese Society of Hematology Chinese Medical Association. [Chinese expert consensus on the application of intravenous iron (2019)] [J]. Zhonghua Xue Ye Xue Za Zhi, 2019, 40(5):358-362.
[35]Wang WN, Zhang WL, Sun T, Ma FZ, Su S, Xu ZG. Effect of peritoneal dialysis versus hemodialysis on renal anemia in renal in end-stage disease patients: a meta-analysis. Ren Fail 2017; 39(1):59–66.
[36]Fuller DS, Bieber BA, Pisoni RL, Li Y, Morgenstern H, Akizawa T, et al. International comparisons to assess effects of payment and regulatory changes in the United States on anemia practice in patients on hemodialysis: the Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 2016; 27(7):2205–15.
[37]Macdougall IC, Bock AH, Carrera F, et al. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial [J]. BMC Nephrol, 2017,18(1):24.
[38]Roger SD, Gaillard CA, Bock AH, et al. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial [J]. Nephrol Dial Transplant,2017, 32(9):1530-1539.
[39]Nan Chen, Chuanming Hao, Bi-Cheng Liu, et al. Roxadustat Treatment for Anemia in Patients Undergoing LongTerm Dialysis[J]. N Engl J Med, 2019,381(11):1011-1022.
[40]Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010.
[41]Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, double blind, active comparator (DarbepoetinAlfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan[J]. J Am Soc Nephrol, 2020, 31(7): 1628-1639.
[42]Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int 2019; 86(4):845–54.
